Analysts at BofA/Merrill (BAC) downgraded Intercept Pharmaceuticals, Inc. (ICPT) from ‘Buy‘ to ‘Neutral‘ in a research report issued to clients on Tuesday. Intercept’s trailing-12-month revenue is $1.74 million while its return on assets for the same period is (180.8%). Shares of the $6.50 billion market cap company are up 12.03% year-over-year and up 101.27% year-to-date. […] View the full post at: Notable Downgrades: Intercept (ICPT), Radiant Logistics (RLGT), Eleven Biotherapeutics (EBIO), Urban Outfitters (URBN) Related posts: Insider Trading Summary: Notable Transactions (Aug.31-Sept.04) Last Week’s Insider Trading Summary: Notable Purchases/Selling Tracking Insider Trading: Notable Transactions (Sept.01)